Optimizing First‐Line Therapeutics in Non‐Small Cell Lung Cancer: Insights From Joint Modeling and Large‐Scale Data Analysis

ABSTRACT Non‐small cell lung cancer (NSCLC) is often intrinsically resistant to several first‐ and second‐line therapeutics and can rapidly acquire further resistance after a patient begins treatment. Treatment outcomes are, therefore, significantly impacted by the optimization of scheduling. Previo...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Benjamin K. Schneider, Sebastien Benzekry, Jonathan P. Mochel
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-10-01
Colecção:	CPT: Pharmacometrics & Systems Pharmacology
Assuntos:	bevacizumab lung cancer mathematical modeling methodology model based meta analysis non‐linear mixed effects
Acesso em linha:	https://doi.org/10.1002/psp4.70079
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!